《淋巴细胞亚群检测在血液肿瘤中应用的专家共识》解读

Interpretation of experts consensus on the application of lymphocyte subsets in hematologic malignancies

血液肿瘤是一类起源于造血系统的恶性肿瘤,其发生、发展及预后与患者的免疫功能密切相关,其中细胞免疫发挥尤为重要的作用。目前,基于流式细胞术的淋巴细胞亚群检测已被广泛应用于血液肿瘤患者的免疫状态评估、疾病复发或转移风险预测及治疗指导等方面。为了更加深刻地认识淋巴细胞亚群检测在血液肿瘤中的临床价值,加强其检测过程中的质量管理,促进其规范地应用于临床,中国医药质量管理协会医学检验质量管理专业委员会牵头组织国内血液肿瘤诊疗领域多位检验及临床专家,发表了《淋巴细胞亚群检测在血液肿瘤中应用的专家共识》。该解读对该共识进行简要说明,供我国血液肿瘤诊疗相关领域的工作者参考。

Hematological malignancies are malignant tumors those originate from the hematopoietic system.Their occurrence,development and prognosis are closely related to patients'immune function,in which cellular immunity plays a particularly prominent role.At present,the detection of lymphocyte subsets based on flow cytometry(FCM)is widely used in immune status assessment,disease recurrence or metastasis risk prediction and treatment guidance of patients with hematological malignancies.In order to more deeply understand the clinical value of lymphocyte subsets detection in hematologic malignancies,strengthen the quality management in the detection process,and promote its standardized application in clinic,Professional Committee of Medical Laboratory Quality Management of China Quality Association for Pharmaceuticals organized a number of domestic laboratory and clinical experts in the field of hematological malignancies diagnosis and treatment published"Consensus of experts on the application of lymphocyte subsets in hematologic malignancies."This interpretation briefly explains the consensus,which can be used as a reference for practitioners in the field of diagnosis and treatment of hematologic malignancies in China.